PF-114, an original drug product, was given the INN of Vamotinib by the World Health Organization at the 73d Consultation on International Nonproprietary Names (INN).

PF-114, an innovative drug, is intended for the treatment of chronic myelogenous leukemia (CML) resistant to first and second generation anti-CML drugs.

In January 2021, Pharmasyntez-Nord JSC signed a license agreement on the commercialization of PH-114, an innovative drug for the treatment of chronic myelogenous leukemia. As a part of the agreement, Pharmasyntez-Nord JSC undertakes to conduct phase 3 clinical trials of the drug, carry out its state registration and commercialize it.